Cargando…

Impact of lanadelumab on health‐related quality of life in patients with hereditary angioedema in the HELP study

BACKGROUND: An objective of the phase 3 HELP Study was to investigate the effect of lanadelumab on health‐related quality of life (HRQoL) in patients with hereditary angioedema (HAE). METHODS: Patients with HAE‐1/2 received either lanadelumab 150 mg every 4 weeks (q4wks; n = 28), 300 mg q4wks (n = 2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lumry, William R., Weller, Karsten, Magerl, Markus, Banerji, Aleena, Longhurst, Hilary J., Riedl, Marc A., Lewis, Hannah B., Lu, Peng, Devercelli, Giovanna, Jain, Gagan, Maurer, Marcus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	ORIGINAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247292/ https://www.ncbi.nlm.nih.gov/pubmed/33258114 http://dx.doi.org/10.1111/all.14680

Ejemplares similares

Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks
por: Riedl, Marc A., et al.
Publicado: (2020)

Long‐term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study
por: Banerji, Aleena, et al.
Publicado: (2021)

Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies
por: Busse, Paula J., et al.
Publicado: (2018)

Effectiveness of lanadelumab for preventing hereditary angioedema attacks: Subgroup analyses from the HELP study
por: Johnston, Douglas T., et al.
Publicado: (2021)

An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension
por: Riedl, Marc A., et al.
Publicado: (2017)

Lanadelumab for hereditary angioedema
Publicado: (2022)

Pharmacokinetics, Pharmacodynamics, and Exposure‐Response of Lanadelumab for Hereditary Angioedema
por: Wang, Yi, et al.
Publicado: (2020)

Using an extended treatment regimen of lanadelumab in the prophylaxis of hereditary angioedema: a single-centre experience
por: Abuzakouk, Mohamed, et al.
Publicado: (2022)

Hereditary angioedema with C1 inhibitor deficiency: delay in diagnosis in Europe
por: Zanichelli, Andrea, et al.
Publicado: (2013)

Indirect Comparison of Lanadelumab and Intravenous C1-INH Using Data from the HELP and CHANGE Studies: Bayesian and Frequentist Analyses
por: Mendivil, Joan, et al.
Publicado: (2021)

Long-term prophylaxis for hereditary angioedema: Initial experiences with garadacimab and lanadelumab
por: Wong, Jane C.Y., et al.
Publicado: (2023)

WAO Guideline for the Management of Hereditary Angioedema
por: Craig, Timothy, et al.
Publicado: (2012)

Impact of lanadelumab in hereditary angioedema: a case series of 12 patients in Canada
por: Iaboni, Aled, et al.
Publicado: (2021)

Network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema
por: Watt, Maureen, et al.
Publicado: (2023)

Content validation and psychometric evaluation of the Angioedema Quality of Life Questionnaire for hereditary angioedema
por: Vanya, Magdalena, et al.
Publicado: (2023)

Correction to: Content validation and psychometric evaluation of the Angioedema Quality of Life Questionnaire for hereditary angioedema
por: Vanya, Magdalena, et al.
Publicado: (2023)

Lanadelumab Injection Treatment For The Prevention Of Hereditary Angioedema (HAE): Design, Development And Place In Therapy
por: Bova, Maria, et al.
Publicado: (2019)

Experience of lanadelumab administration in hereditary angioedema: A case series of 4 patients in Portugal
por: Bernardino, Ana Graça, et al.
Publicado: (2023)

Safety Aspects and Rational Use of Lanadelumab Injections in the Treatment of Hereditary Angioedema (HAE): Clinical Insights
por: Petkova, Elena, et al.
Publicado: (2022)

Optimal Management of Hereditary Angioedema: Shared Decision-Making
por: Banerji, Aleena, et al.
Publicado: (2021)

Consider Hereditary Angioedema in the Differential Diagnosis for Unexplained Recurring Abdominal Pain
por: Staller, Kyle, et al.
Publicado: (2022)

Successful use of lanadelumab in a patient with hereditary angioedema with normal C1 inhibitor and negative genetic testing
por: Adatia, Adil, et al.
Publicado: (2023)

Hereditary Angioedema: The Economics of Treatment of an Orphan Disease
por: Lumry, William Raymond
Publicado: (2018)

Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study
por: Lumry, William R., et al.
Publicado: (2021)

Attenuated androgen discontinuation in patients with hereditary angioedema: a commented case series
por: Maurer, Marcus, et al.
Publicado: (2022)

Management of acute attacks of hereditary angioedema: potential role of icatibant
por: Longhurst, Hilary J
Publicado: (2010)

Correction to: Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study
por: Lumry, William R., et al.
Publicado: (2021)

Treatment of hereditary angioedema—single or multiple pathways to the rescue
por: Valerieva, Anna, et al.
Publicado: (2022)

Improvement in diagnostic delays over time in patients with hereditary angioedema: findings from the Icatibant Outcome Survey
por: Zanichelli, Andrea, et al.
Publicado: (2018)

Transition to lanadelumab‐flyo from three medications for a hereditary angioedema patient with a variant in the SYTL2 gene: A case report
por: Burns, Stephanie, et al.
Publicado: (2021)

Effectiveness and safety of lanadelumab in ethnic and racial minority subgroups of patients with hereditary angioedema: results from phase 3 studies
por: Craig, Timothy J., et al.
Publicado: (2022)

Considerations in the management of hereditary angioedema due to C1-INH deficiency in women of childbearing age
por: Hsu, Florence Ida, et al.
Publicado: (2022)

Optimum Use of Acute Treatments for Hereditary Angioedema: Evidence-Based Expert Consensus
por: Longhurst, Hilary
Publicado: (2018)

Analysis of icatibant for the treatment of laryngeal hereditary angioedema attacks in the FAST-3 study
por: Yang, William, et al.
Publicado: (2014)

Correction: Considerations in the management of hereditary angioedema due to C1-INH deficiency in women of childbearing age
por: Hsu, Florence Ida, et al.
Publicado: (2022)

Clinical characteristics and burden of illness in patients with hereditary angioedema: findings from a multinational patient survey
por: Mendivil, Joan, et al.
Publicado: (2021)

Advances in Hereditary Angioedema: The Prevention of Angioedema Attacks With Subcutaneous C1-Inhibitor Replacement Therapy
por: Lumry, William, et al.
Publicado: (2020)

The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and update
por: Maurer, Marcus, et al.
Publicado: (2022)

Hereditary Angioedema Attacks Resolve Faster and Are Shorter after Early Icatibant Treatment
por: Maurer, Marcus, et al.
Publicado: (2013)

Treatment patterns and healthcare resource utilization among patients with hereditary angioedema in the United States
por: Riedl, Marc A, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_u2igusvnk2qjcc98vadqa0p3st